FDA Cites Terramed in 2026-10-01 Warning Letter — Unapproved New Drugs
Letter issued · posted to fda.gov .
Subject as published: Unapproved New Drugs
TL;DR
Here's the summary: On October 1, 2026, the FDA's Center for Drug Evaluation and Research (CDER) issued a warning letter to Terramed (CEO Krystsina Uradzimskaya, La Mesa, CA) regarding unapproved new drugs marketed on terramed.info: "Genital Herpes Intimate Wash," "HerpCare Ointment," "HerpCare Spray," and "HerpCare Genital Wart Remover Ointment" (Reference 735070). The FDA states these products make disease-treatment claims for sexually transmitted infections without FDA approval, violating sections 301(d) and 505(a) of the FD&C Act, and notes that unapproved STI drugs present serious public health risks including potential for patients to forgo appropriate medical care. The letter directs Terramed to promptly address violations or face regulatory action including seizure and injunction.
Argus analysis
# FDA Warning Letter Analysis: Terramed
**Company and Violations**
Terramed, based in La Mesa, California, received a warning letter from FDA's Center for Drug Evaluation and Research (CDER) on October 1, 2026, for marketing four unapproved drug products: "Genital Herpes Intimate Wash," "HerpCare Ointment," "HerpCare Spray," and "HerpCare Genital Wart Remover Ointment." The FDA conducted a website review in July 2026 and determined these products violate federal law by making disease-treatment claims without approval. The agency emphasized that unapproved drugs marketed for sexually transmitted infections present serious public health risks, as consumers may delay appropriate medical care, increasing complications including infertility and sepsis, and may unknowingly transmit infections to partners.
**Regulatory Citations and Meaning**
The violations center on sections 301(d) and 505(a) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 331(d) and 355(a)), which prohibit introducing unapproved new drugs into interstate commerce. Under section 201(g)(1) (21 U.S.C. 321(g)(1)), products are classified as drugs if labeled to treat, cure, mitigate, or prevent disease or affect body functions. The FDA found Terramed's website labeling explicitly claimed symptom relief and treatment support for genital herpes and warts, establishing drug intent. Products claiming homeopathic status receive no exemption—they remain subject to identical approval requirements as conventional drugs under current FDA guidance.
**Response Timeline and Industry Implications**
Terramed has 15 business days from letter receipt to submit written corrective actions to FDAAdvisory@fda.hhs.gov. Compliance officers in the intimate care and OTC pharmaceutical sectors should monitor whether Terramed removes products from commerce, reformulates without disease claims, or pursues formal drug approval. The letter's emphasis on STI products suggests heightened FDA scrutiny of this category. Warning letters typically precede enforcement action including seizure or injunction if violations persist.
Severity context
Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
Regulatory background
Unapproved-drug letters cite 21 USC 355 (NDA requirement) or 21 USC 331(d) (introduction into interstate commerce). FDA increasingly applies these provisions to homeopathic products, kratom, and certain compounded preparations.
What peer compliance teams typically do next
Most compliance officers at peer companies use a Warning Letter against a named entity as a checklist for their own CAPA program. Common steps: pull the verbatim FDA letter; map each cited 21 CFR section against the team’s SOP library; confirm CAPA coverage; brief the QMR (Quality Management Review) on whether the cited subject matter is in scope for the next internal audit. The 15-business-day response window applies to the cited entity, not to peers — but a documented internal review against the cited subjects is what regulators expect to see if a peer is later inspected on the same topic.
Excerpt from the FDA Warning Letter (public domain, 17 USC §105)
WARNING LETTER Terramed MARCS-CMS 735070 — October 01, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: VIA ELECTRONIC MAIL READ/DELIVERY RECEIPT REQUESTED Product: Drugs Over-the-Counter Drugs Recipient: Recipient Name Krystsina Uradzimskaya Recipient Title CEO Terramed 10731 Queen Ave La Mesa , CA 91941 United States support@terramed.info info@puritycosmetics.com Issuing Office: Center for Drug Evaluation and Research (CDER) United States October 1, 2026 9310 Towne Center Dr Unit 72 San Diego, California, 92121 WARNING LETTER Reference Number: 735070 To Krystsina Uradzimskaya: This warning letter advises you of significant violations observed during a U.S. Food and Drug Administration (FDA) review of your website, https://terramed.info, and provides you an opportunity to address them. Promptly address any violations described herein without delay, including ensuring that appropriate resources are allocated to fully address them and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that may exist in connection with your products or operations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately any address violations may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. As discussed below, the “Genital Herpes Intimate Wash,” “HerpCare Ointment,” “HerpCare Spray,” and “HerpCare Genital Wart Remover Ointment” products on your website are unapproved new drugs. Unapproved drug products marketed for the treatment of sexually transmitted infections (STIs) and/or their symptoms and sold directly to consumers present a serious public health concern. Individuals who rely on these products may forgo timely, appropriate medical care, increasing their risk of severe complications such as infertility, sepsis, and death. Further, a false sense of having been adequately treated may lead individuals to unknowingly transmit infections to their partners. FDA has not approved any over-the-counter (OTC) drug product for the treatment, cure, mitigation, or prevention of any STI. Effective treatment requires diagnosis and supervision by a licensed healthcare professional. FDA Review Violations were identified and documented during a review of your website https://terramed.info/ in July 2026. Based on our review, “Genital Herpes Intimate Wash,” “HerpCare Ointment,” “HerpCare Spray,” and “HerpCare Genital Wart Remover Ointment” are unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a). As explained further below, introducing or delivering these products for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a). This review was conducted as part of FDA’s public health responsibility to protect the publ…
Excerpt only. The full verbatim Warning Letter is the source of truth — always read the original before regulatory decisions.
The verbatim FDA Warning Letter is the source of truth. Always read the original before acting on any analysis or summary on this page.
Read the full letter on fda.gov ↗Frequently asked questions
- Has Terramed had FDA enforcement actions before?
- This is the only FDA Warning Letter Argus HQ has on file for Terramed as of 2026-10-06. Argus ingests new FDA enforcement records daily.
- What FDA violations was Terramed cited for?
- The FDA Warning Letter to Terramed (issuing office: Center for Drug Evaluation and Research (CDER)) cites: Unapproved New Drugs. Classification: Unapproved drug.
- When did FDA issue the warning letter to Terramed?
- FDA issued the letter (MARCS-CMS 735070) on 2026-10-01 and posted it publicly on fda.gov on 2026-10-06.
- Is the FDA warning letter to Terramed publicly available?
- Yes. The full verbatim letter is published at fda.gov. Argus HQ links directly to the source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/terramed-735070-10012026.
argus.hq
Don’t find out about the next one six weeks late.
Argus reads every FDA Warning Letter the day it publishes, summarizes it against your watchlist, and lands the ones touching your business in your inbox at 6am ET. Plans from $99/month. Cancel any time.
methodology
The analysis above is produced by Anthropic Claude Haiku 4.5 against the verbatim FDA Warning Letter excerpt and is brand-voice lint-checked before publish. The TL;DR is the same summary that ships in the customer email digest. Severity is auto-classified by Argus from the subject string and letter body using rules documented in lib/ingestion/fda-warning-letters.ts.
Argus HQ is informational only. Summaries and analyses are AI-generated and may contain errors, misclassifications, or omissions. Verify against the FDA source URL above. Argus HQ is not a law firm, accounting firm, or regulatory agency, and provides no legal, accounting, financial, medical, or regulatory advice.
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). FDA Cites Terramed in 2026-10-01 Warning Letter — Unapproved New Drugs. Digital Empire Holdings LLC. Retrieved from https://argushq.ai/fda/warning-letter/fda-wl-terramed-2026-10-01-unapproved-drug
"FDA Cites Terramed in 2026-10-01 Warning Letter — Unapproved New Drugs." Argus HQ Research, Digital Empire Holdings LLC, 2026, argushq.ai/fda/warning-letter/fda-wl-terramed-2026-10-01-unapproved-drug.
Argus HQ Research. "FDA Cites Terramed in 2026-10-01 Warning Letter — Unapproved New Drugs." Digital Empire Holdings LLC. Accessed October 7, 2026. https://argushq.ai/fda/warning-letter/fda-wl-terramed-2026-10-01-unapproved-drug.
@misc{argushq_argushq_ai_fda_warning_letter_fda_wl_terramed_2026_10_01_unapproved_drug_2026,
title = {FDA Cites Terramed in 2026-10-01 Warning Letter — Unapproved New Drugs},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire Holdings LLC},
url = {https://argushq.ai/fda/warning-letter/fda-wl-terramed-2026-10-01-unapproved-drug},
note = {Accessed: October 7, 2026}
}